Author:
Dragovich Tomislav,Huberman Mark,Von Hoff Daniel D.,Rowinsky Eric K.,Nadler Paul,Wood Debra,Hamilton Marta,Hage George,Wolf Julie,Patnaik Amita
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference28 articles.
1. Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130
2. Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413
3. Rothenberg ML, Moore MJ, Cripps MC et al (1996) A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347–353
4. Tempero M, Plunkett W, Ruiz Van Haperen V et al (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408
5. O’Rielly E, Abou-Alfa GK, Letourneau R et al (2004) A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs gemcitabine alone in advanced pancreatic cancer. ASCO Annu Meet Proc 22:315s
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献